Chronic Lymphocytic Leukemia

The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with CLL.

Jacqueline Claudia Barrientos, MD, discusses the appropriate treatment strategies for elderly patients with chronic lymphocytic leukemia.

Kanti R. Rai, MD, discusses older populations with chronic lymphocytic leukemia.

Loretta J. Nastoupil, MD, discusses the study of the triplet of ublituximab, umbralisib (TGR-1202) and ibrutinib in CLL.

Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, discusses the management of elderly patients with chronic lymphocytic leukemia (CLL).

The next frontier in advancing the field of chronic lymphocytic leukemia (CLL) is identifying patients who will not experience long-term progression-free survival on novel agents.

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the importance of fluorescence in situ hybridization (FISH) testing for patients with chronic lymphocytic leukemia (CLL).

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses combinations with ibrutinib (Imbruvica) in chronic lymphocytic leukemia.

Alessandra Ferrajoli, MD, discusses the risks of developing secondary malignancies in patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses novel agents and combinations in CLL, as well as the critical importance of FISH and IGHV testing for patient selection in this population.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for newer therapies in the treatment of chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia.

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia.

Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),

The FDA has accepted a biologics license application for the rituximab biosimilar Rixathon, according to Sandoz, the company developing the treatment.

The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies.

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).

Duvelisib reduced the risk of disease progression or death by 48% versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the long-term impact that ibrutinib (Imbruvica) has on patients with chronic lymphocytic leukemia (CLL).

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).